Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Computer Resources
      • Highly Cited Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Early Career Award
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citations
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Research
Cancer Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Computer Resources
      • Highly Cited Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Early Career Award
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citations
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Tumor Biology

Targeted Disruption of the β1 Integrin Gene in a Lymphoma Cell Line Greatly Reduces Metastatic Capacity

Peter J. M. Stroeken, Ellen A. M. van Rijthoven, Martin A. van der Valk and Ed Roos
Peter J. M. Stroeken
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ellen A. M. van Rijthoven
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Martin A. van der Valk
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ed Roos
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published April 1998
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

Integrins have been implicated in tumor metastasis. To investigate this, we generated β1 integrin-negative double knockout (DKO) mutants of the highly metastatic ESb murine T-lymphoma cell line. The in vivo growth capacity of the mutants, which had lost α4β1 and α6β1 expression, was not altered, but their metastatic capacity was greatly reduced. Tail vein injection of 104 ESb and single-knockout cells led to death of all animals within 9–11 days. In contrast, only one-half of the animals injected with 104 DKO cells died, but much later, after 20–60 days. The other one-half remained disease-free for up to 100 days. Whereas ESb and single-knockout cells disseminated predominantly to liver and spleen, metastasis of DKO cells to these organs was rare, even after this prolonged period. Instead, skeletal muscles were invaded extensively. Metastatic capacity was largely restored in a DKO clone, which had been transfected with β1 cDNA and expressed β1 at similar levels as ESb cells. We conclude that β1 integrins are essential for efficient liver and spleen colonization by the ESb lymphoma.

Footnotes

  • ↵1 To whom requests for reprints should be addressed, at Division of Cell Biology, The Netherlands Cancer Institute, 121 Plesmanlaan, 1066 CX Amsterdam, the Netherlands. Phone: 31-20-5121931; Fax: 31-20-5121944; E-mail: eroos@nki.nl.

  • Received October 3, 1997.
  • Accepted February 2, 1998.
  • ©1998 American Association for Cancer Research.
PreviousNext
Back to top
April 1998
Volume 58, Issue 7
  • Table of Contents
  • Table of Contents (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)

Sign up for alerts

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Targeted Disruption of the β1 Integrin Gene in a Lymphoma Cell Line Greatly Reduces Metastatic Capacity
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Targeted Disruption of the β1 Integrin Gene in a Lymphoma Cell Line Greatly Reduces Metastatic Capacity
Peter J. M. Stroeken, Ellen A. M. van Rijthoven, Martin A. van der Valk and Ed Roos
Cancer Res April 1 1998 (58) (7) 1569-1577;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Targeted Disruption of the β1 Integrin Gene in a Lymphoma Cell Line Greatly Reduces Metastatic Capacity
Peter J. M. Stroeken, Ellen A. M. van Rijthoven, Martin A. van der Valk and Ed Roos
Cancer Res April 1 1998 (58) (7) 1569-1577;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

Tumor Biology

  • Abstract 6119: RNAi rat models for drug discovery
  • Abstract 3834: Histone methyltransferase SET8 is regulated by miR-192/-215 and induces oncogene-induced senescence via p53-dependent DNA damage in human gastric carcinoma cells
  • Abstract 3788: CircHMGCS1 interacts with RNA binding protein HuR and maintains stem-like cells in gliomas
Show more Tumor Biology

Articles

  • Genetic Control of Programmed Cell Death in the Nematode Caenorhabditis elegans
  • Membership of Advisory Council
  • The Prizes
Show more Articles
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement